24 November 2017
News and Views
Links and Services
A study in the latest issue of Hepatology examines costs of telaprevir-based triple therapy for hepatitis C.
In registration trials, triple therapy with telaprevir, pegylated interferon, and ribavirin achie
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors